Evicenter
MarkdownMedical informationP&T meetings
Envudeucitinib (ESK-001)

Moderate-to-severe plaque psoriasis

Also known as FTP-637
Manufacturer
Alumis
Launch
Not announced
Last updated
277 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

TYK2 inhibitors

15 evidence topics · 11 sources

Trial PSO-1 efficacy versus placebo and apremilast: deucravacitinib label
Endpoint, n (%)SOTYKTU (N=330)Placebo (N=166)Apremilast (N=168)
sPGA 0/1, Week 16“178 (54)”“12 (7)”“54 (32)”
PASI 75, Week 16“193 (58)”“21 (13)”“59 (35)”
PASI 90, Week 16“118 (36)”“7 (4)”“33 (20)”
Endpoint at Week 24, Trial PSO-1, n (%)SOTYKTU (N=330)Apremilast (N=168)
PASI 75“228 (69)”“64 (38)”
PASI 90“140 (42)”“37 (22)”
Adverse reactions through week 16 in Trials PSO-1 and PSO-2: deucravacitinib label
Adverse reaction, n (%)SOTYKTU 6 mg once daily (N=840)Placebo (N=419)
Upper respiratory infections“161 (19.2)”“62 (14.8)”
Blood creatine phosphokinase increased“23 (2.7)”“5 (1.2)”
Herpes simplex“17 (2)”“1 (0.2)”
Mouth ulcers“16 (1.9)”“0 (0.0)”
Folliculitis“14 (1.7)”“0 (0.0)”
Guideline statements: deucravacitinib infections, herpes zoster, laboratory changes, and malignancies